Status:
COMPLETED
A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients
Lead Sponsor:
Pfizer
Conditions:
Hepatitis C
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
Assess the safety, tolerability and pharmacokinetics of multiple oral doses of PF-00868554 in HCV positive patient volunteers
Eligibility Criteria
Inclusion
- HCV RNA ≥ 100,000 IU/mL at screening
- Genotype 1a or 1b
Exclusion
- Current or prior treatment with IFN and/or RBV
- Evidence of decompensated liver disease
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00445315
Start Date
January 1 2007
End Date
June 1 2008
Last Update
February 17 2014
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Brussels, Belgium, 1070
2
Pfizer Investigational Site
Berlin, Germany, 10117
3
Pfizer Investigational Site
Berlin, Germany, 12351
4
Pfizer Investigational Site
Dundee, United Kingdom, DD1 9SY